Compare Stocks: CVRS, IRTC, PLSE, and ATRC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$58.33 +1.8%	$52.05	$25.36 ▼ $61.70	$2.96B	1.24	875,831 shs	82,389 shs
CVRS Corindus Vascular Robotics	$4.27	$4.27	$0.78 ▼ $4.40	$891.09M	N/A	1.99 million shs	N/A
IRTC iRhythm Technologies	$107.70 +1.6%	$116.42	$100.70 ▼ $212.00	$3.54B	1.45	594,826 shs	64,351 shs
PLSE Pulse Biosciences	$46.41 +0.2%	$49.63	$12.56 ▼ $58.90	$3.28B	1.57	390,034 shs	39,888 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	+0.76%	+7.48%	+2.71%	+60.86%	+61.91%
CVRS Corindus Vascular Robotics	0.00%	0.00%	0.00%	0.00%	0.00%
IRTC iRhythm Technologies	-1.54%	+1.01%	-7.56%	-8.06%	-40.03%
PLSE Pulse Biosciences	-4.57%	-5.64%	-14.55%	+69.17%	+168.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$58.33 +1.8%	$52.05	$25.36 ▼ $61.70	$2.96B	1.24	875,831 shs	82,389 shs
CVRS Corindus Vascular Robotics	$4.27	$4.27	$0.78 ▼ $4.40	$891.09M	N/A	1.99 million shs	N/A
IRTC iRhythm Technologies	$107.70 +1.6%	$116.42	$100.70 ▼ $212.00	$3.54B	1.45	594,826 shs	64,351 shs
PLSE Pulse Biosciences	$46.41 +0.2%	$49.63	$12.56 ▼ $58.90	$3.28B	1.57	390,034 shs	39,888 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	+0.76%	+7.48%	+2.71%	+60.86%	+61.91%
CVRS Corindus Vascular Robotics	0.00%	0.00%	0.00%	0.00%	0.00%
IRTC iRhythm Technologies	-1.54%	+1.01%	-7.56%	-8.06%	-40.03%
PLSE Pulse Biosciences	-4.57%	-5.64%	-14.55%	+69.17%	+168.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRC AtriCure	2.58	Moderate Buy	$54.10	-7.24% Downside
CVRS Corindus Vascular Robotics	0.00	N/A	N/A	N/A
IRTC iRhythm Technologies	2.94	Moderate Buy	$178.79	66.01% Upside
PLSE Pulse Biosciences	2.86	Moderate Buy	$60.20	29.71% Upside

Current Analyst Ratings Breakdown

Latest CVRS, IRTC, PLSE, and ATRC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	PLSE Pulse Biosciences	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$55.00
10/13/2026	PLSE Pulse Biosciences	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$35.00 ➝ $60.00
10/12/2026	IRTC iRhythm Technologies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/12/2026	ATRC AtriCure	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$55.00 ➝ $63.00
10/8/2026	ATRC AtriCure	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
10/6/2026	PLSE Pulse Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$43.00 ➝ $58.00
10/6/2026	IRTC iRhythm Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$168.00 ➝ $150.00
10/5/2026	IRTC iRhythm Technologies	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$192.00 ➝ $194.00
10/2/2026	ATRC AtriCure	Freedom Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/23/2026	PLSE Pulse Biosciences	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$70.00
9/23/2026	PLSE Pulse Biosciences	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$70.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRC AtriCure	$534.53M	5.55	$0.32 per share	181.70	$9.89 per share	5.90
CVRS Corindus Vascular Robotics	N/A	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	$825.34M	4.30	N/A	N/A	$4.74 per share	22.72
PLSE Pulse Biosciences	$350K	9,388.08	N/A	N/A	$1.19 per share	39.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRC AtriCure	-$11.45M	$0.21	277.27	129.61	N/A	1.85%	2.34%	1.77%	11/3/2026 (Confirmed)
CVRS Corindus Vascular Robotics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	-$44.55M	-$0.43	N/A	74.27	N/A	-1.69%	10.11%	1.53%	10/29/2026 (Estimated)
PLSE Pulse Biosciences	-$72.78M	-$1.18	N/A	N/A	N/A	-6,755.78%	-94.42%	-79.96%	11/4/2026 (Estimated)

Latest CVRS, IRTC, PLSE, and ATRC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	PLSE Pulse Biosciences	-$0.35	N/A	N/A	N/A	$0.52 million	N/A
11/3/2026	Q3 2026	ATRC AtriCure	-$0.0427	N/A	N/A	N/A	$151.15 million	N/A
10/29/2026	Q3 2026	IRTC iRhythm Technologies	$0.0230	N/A	N/A	N/A	$222.24 million	N/A
8/6/2026	Q2 2026	IRTC iRhythm Technologies	-$0.04	$0.58	+$0.62	-$0.01	$219.30 million	$224.17 million
8/6/2026	Q2 2026	PLSE Pulse Biosciences	-$0.2933	-$0.36	-$0.0667	-$0.36	$0.53 million	$0.43 million
7/23/2026	Q2 2026	ATRC AtriCure	-$0.0017	$0.18	+$0.1817	$0.18	$151.80 million	$153.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
CVRS Corindus Vascular Robotics	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRC AtriCure	0.14	4.22	3.19
CVRS Corindus Vascular Robotics	N/A	N/A	N/A
IRTC iRhythm Technologies	3.50	3.86	3.74
PLSE Pulse Biosciences	N/A	9.63	9.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRC AtriCure	99.11%
CVRS Corindus Vascular Robotics	N/A
IRTC iRhythm Technologies	N/A
PLSE Pulse Biosciences	76.95%

Insider Ownership

Company	Insider Ownership
ATRC AtriCure	4.00%
CVRS Corindus Vascular Robotics	N/A
IRTC iRhythm Technologies	0.98%
PLSE Pulse Biosciences	74.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRC AtriCure	1,350	50.87 million	48.83 million	Optionable
CVRS Corindus Vascular Robotics	90	208.69 million	N/A	Not Optionable
IRTC iRhythm Technologies	2,400	32.96 million	32.64 million	Optionable
PLSE Pulse Biosciences	116	70.80 million	18.41 million	Optionable

CVRS, IRTC, PLSE, and ATRC Headlines

Recent News About These Companies

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

October 14 at 9:14 AM | marketscreener.comM

Pulse Biosciences, Inc. Announces Commercial And Clinical Partnership With The Clayman Thyroid Center At The Hospital For Endocrine Surgery

October 14 at 9:14 AM | marketscreener.comM

Pulse Biosciences Partners With Clayman Thyroid Center To Expand Thyroid Nodule Treatment

October 14 at 9:14 AM | rttnews.com

Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says

October 13 at 6:46 PM | finance.yahoo.com

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 9, 2026

October 12 at 12:56 PM | biospace.comB

Head-To-Head Contrast: Pulse Biosciences (NASDAQ:PLSE) and NexGel (NASDAQ:NXGL)

October 11, 2026 | americanbankingnews.com

Why Pulse Biosciences (PLSE) Is Up 12.3% After Full NANOPULSE-AF Enrollment And nPulse Spotlight

October 10, 2026 | finance.yahoo.com

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2026 | businesswire.com

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

October 8, 2026 | finance.yahoo.com

Canaccord Genuity Sticks to Its Buy Rating for Pulse Biosciences (PLSE)

October 8, 2026 | theglobeandmail.com

Pulse Biosciences stock reaches 164 patient study target

October 8, 2026 | ad-hoc-news.deA

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

October 7, 2026 | tmcnet.com

Pulse Biosciences Reaches Enrollment Target in Nanopulse-AF Study

October 7, 2026 | marketscreener.comM

Pulse Biosciences, Inc. Achieves Enrollment Target In NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System For Atrial Fibrillation Treatment

October 7, 2026 | marketscreener.comM

Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Target Price of $50.20

October 6, 2026 | americanbankingnews.com

Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20

October 6, 2026 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down - Time to Sell?

October 5, 2026 | marketbeat.com

Pulse Biosciences stock faces Oppenheimer meeting after 3.87 percent fall

October 4, 2026 | ad-hoc-news.deA

Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data

October 3, 2026 | finance.yahoo.com

Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 6.1% - Here's Why

September 29, 2026 | marketbeat.com

Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation

September 27, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRS, IRTC, PLSE, and ATRC Company Descriptions

AtriCure NASDAQ:ATRC

$58.32 +1.03 (+1.79%)

As of 10:57 AM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Corindus Vascular Robotics NYSEAMERICAN:CVRS

$4.27 0.00 (0.00%)

As of 11/27/2019

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.

iRhythm Technologies NASDAQ:IRTC

$107.70 +1.65 (+1.55%)

As of 10:57 AM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Pulse Biosciences NASDAQ:PLSE

$46.41 +0.09 (+0.19%)

As of 10:57 AM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVRS, IRTC, PLSE, and ATRC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVRS, IRTC, PLSE, and ATRC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVRS, IRTC, PLSE, and ATRC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRS, IRTC, PLSE, and ATRC Company Descriptions

AtriCure NASDAQ:ATRC

Corindus Vascular Robotics NYSEAMERICAN:CVRS

iRhythm Technologies NASDAQ:IRTC

Pulse Biosciences NASDAQ:PLSE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVRS, IRTC, PLSE, and ATRC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVRS, IRTC, PLSE, and ATRC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVRS, IRTC, PLSE, and ATRC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRS, IRTC, PLSE, and ATRC Company Descriptions

AtriCure NASDAQ:ATRC

Corindus Vascular Robotics NYSEAMERICAN:CVRS

iRhythm Technologies NASDAQ:IRTC

Pulse Biosciences NASDAQ:PLSE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools